Page 77 - Haematologica-5

DCC-2618: a new drug against mastocytosis
3540-3551.
40. Peter B, Gleixner KV, Cerny-Reiterer S, et al.
Polo-like kinase-1 as novel target in neoplas- tic mast cells: demonstration of growth- inhibitory effects of siRNA and the Polo- like kinase-1 targeting drug BI 2536. Haematologica. 2011;96(5):672-680.
41. Wimazal F, Jordan JH, Sperr WR, et al. Increased angiogenesis in the bone marrow of patients with systemic mastocytosis. Am J Pathol. 2002;160(5):1639-1645.
42. Peter B, Winter GE, Blatt K, et al. Target inter- action profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth. Leukemia. 2016;30(2):464-472.
43. Janku F, Razak ARA, Gordon MS, et al. Pharmacokinetic-driven phase I study of DCC-2618, a pan-KIT and PDGFRA
inhibitor, in patients with gastrointestinal stroma tumor (GIST) and other solid tumors. J Clin Oncol. 2017;35:15(S)2515.
44. Ustun C, Arock M, Kluin-Nelemans HC, et al. Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. Haematologica. 2016;101(10): 1133-1143.
45. Jawhar M, Schwaab J, Schnittger S, et al. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced sys- temic mastocytosis. Leukemia. 2016;30(1): 136-143.
46. Gleixner KV, Mayerhofer M, Cerny-Reiterer S, et al. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mas- tocytosis: role of Lyn and BTK activation and disruption by dasatinib and bosutinib.
Blood. 2011;118(7):1885-1898.
47. Wilson TM, Maric I, Simakova O, et al.
Clonal analysis of NRAS activating muta- tions in KIT-D816V systemic mastocytosis. Haematologica. 2011;96(3):459-463.
48. Schwaab J, Schnittger S, Sotlar K, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013;122(14):2460-2466.
49. Bibi S, Langenfeld F, Jeanningros S, et al. Molecular defects in mastocytosis: KIT and beyond KIT. Immunol Allergy Clin North Am. 2014;34(2):239-262.
50. Damaj G, Joris M, Chandesris O, et al., ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS One. 2014;9(1):e85362.
haematologica | 2018; 103(5)
809